404
+1-313-307-4176
sales@stratviewresearch.com
Generic Injectables Market Growth & Forecast
Generic Injectables Market Size, Share, Trend, Forecast, & Industry Analysis: 2023-2028
The generic injectables market is estimated to grow from USD 122.4 billion in 2022 to USD 250.13 billion by 2028 at a healthy CAGR of 12.60% during the forecast period.
Wish to get a Free Sample? Register Here.
A generic injectable is a drug that has the same active pharmaceutical ingredient as its branded compliment. These drugs are not protected by patents. A generic injectable is also alike to its branded counterpart in terms of strength, safety, performance, dosage form, quality, and route of administration. Unlike branded injectables, the generic injectable is cheaper than the ones used for cancer therapies.
|
Generic Injectables Market Report Overview |
|
|
Market Size in 2028 |
USD 122.4 Billion |
|
Market Size in 2022 |
USD 250.13 Billion |
|
Market Growth (2023-2028) |
CAGR of 12.60% |
|
Base Year of Study |
2022 |
|
Trend Period |
2017-2021 |
|
Forecast Period |
2023-2028 |
The following are some of the key players operating in the global generic injectables market are-
The generic injectables market is driven by a host of factors, some of which are noted below:
The rising investment by government bodies for the development of generic drugs. It is aimed at promoting generic injectables to lower healthcare expenditure. Also, drug shortages in confluence with quick approvals by the USFDA further boost product usage. Moreover, numerous branded injectables firms are also expected to lose their patient protection in the coming years.
To Get the full scope of the report, Register Here.
Here are some specific market trends to watch in the generic injectables market:
Increased demand for large molecule injectables: The use of large molecule injectables in the treatment of chronic illnesses is growing, such as proteins and monoclonal antibodies. It is anticipated that this pattern will persist, propelling the need for large-molecule injectable generics.
Growing focus on biosimilars: Although they cost less, biosimilars and biological medications are quite comparable. The market for generic biosimilars is anticipated to grow as biosimilars continue to gain traction.
Expansion into emerging markets: In the coming years, emerging markets are anticipated to play a significant role in propelling the generic injectables market's expansion. These markets have sizable and expanding populations, and they are using generic medications more frequently.
The market has been classified into large-molecule injectables and small-molecule injectables. The large molecule injectables segment accounted for the largest market in 2022 & is expected to remain the largest market during the forecast period.
Significant research and development activities for biosimilar products, growing demand for affordable biological products, and expected patent expiry of branded molecules are likely to bolster the segment's growth.
The market has been classified into oncology, infectious diseases, cardiology, diabetes, immunology, & others. The oncology segment occupied a significant market share in 2022 & is expected to remain dominant during the forecast period. The rising global prevalence of cancer has raised the demand for oncology therapies, especially injectable drugs. As the number of cancer patients increases, the necessity for cost-effective treatment alternatives becomes crucial, fueling demand for generic injectables in oncology.
Because of the complexity and high costs connected with the development of innovative cancer medicines, prospects for generic injectables have arisen. Generic injectables are less expensive than branded cancer medications, making them more accessible to a larger patient group. This element of affordability has accelerated the use of generic injectables in oncology, particularly in areas with limited healthcare resources.
North American generic injectables market accounted for the highest share in 2022 and is expected to grow at a robust CAGR during the review period. The market growth is mainly attributed to the large presence of a properly structured healthcare sector, rising number of abbreviated new drug application (ANDA) approvals, increasing prevalence of lifestyle diseases, growing demand for inexpensive biosimilar products, and easy availability of reimbursement policies with broader coverage.
On the other hand, Asia Pacific is expected to grow at a healthy CAGR during the review period due to a surge in the healthcare expenditure by the government, strong prevalence of infectious diseases such as typhoid, diarrhea, malaria, and cholera, rising increasing prevalence of cancer, and soaring demand for inexpensive medicines, further bolsters the regional market growth.
This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.
The generic injectables market is segmented into the following categories:
By Product
By Application
By Region
Want to get more details about the segmentations, Click here.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.
What Deliverables Will You Get in this Report?
|
Key questions this report answers |
Relevant contents in the report |
|
How big is the sales opportunity? |
In-depth Analysis of the generic injectables market |
|
How lucrative is the future? |
The market forecast and trend data and emerging trends |
|
Which regions offer the best sales opportunities? |
Global, regional, and country-level historical data and forecasts |
|
Which are the most attractive market segments? |
Market segment analysis and Forecast |
|
Which are the top players and their market positioning? |
Competitive landscape analysis, Market share analysis |
|
How complex is the business environment? |
Porter’s five forces analysis, PEST analysis, Life cycle analysis |
|
What are the factors affecting the market? |
Drivers & challenges |
|
Will I get the information on my specific requirement? |
10% free customization |
The target audience of the generic injectables market includes-
The COVID-19 pandemic has moderately affected the generic injectables industry. The rapid spread of COVID-19 has resulted in several thousands of hospital admissions. The focus of healthcare professionals has been shifted toward the treatment of COVID-19-infected patients, which affected the treatment of non-emergency medical conditions, amid the pandemic.
This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.
More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.
We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.
Stratview Research offers one of the following free customization options to our respectable clients:
Company Profiling
Competitive Benchmarking
Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances
Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.
A generic injectable is a drug that has the same active pharmaceutical ingredient as its branded compliment. These drugs are not protected by patents. A generic injectable is also alike to its branded counterpart in terms of strength, safety, performance, dosage form, quality, and route of administration. Unlike branded injectables, the generic injectable is cheaper than the ones used for cancer therapies.
The market is estimated to reach USD 250.13 billion by 2028.
The market is estimated to grow by USD 122.4 billion in 2022.
The market is estimated to grow at a healthy CAGR of 12.60% during the forecast period.
The target audience of the market includes- vendors, manufacturers, distributors, organizations, and government bodies.
Key players operating in the market are- Pfizer (US), Sandoz International (Germany), Baxter, Fresenius (Germany), Mylan, Teva Pharmaceutical (Israel), Hikma Pharmaceuticals (UK), Lupin Pharmaceuticals (India), Sanofi (France), Biocon (India).
North America accounted for the highest share in 2022 and is expected to grow at a robust CAGR during the review period.
The market is majorly driven by rising investment by government bodies for the development of generic drugs. It is aimed at promoting generic injectables to lower healthcare expenditure.
WE ACCEPT
